April 25, 2013- Interviewed by Steven E. Greer, MD
With former President George W. Bush receiving a coronary stent and cardiac chest CT-scan, Continue reading
April 25, 2013- Interviewed by Steven E. Greer, MD
With former President George W. Bush receiving a coronary stent and cardiac chest CT-scan, Continue reading
April 24, 2013 By Steven E. Greer, MD
In July of 2012, the New York Times reported on an FDA scandal of the agency spying on internal Continue reading
April 20, 2013 By Steven E. Greer, MD
Only two days after the April 15th Boston Marathon terrorist bombings, Harvard surgeon Atul Continue reading
Interviewed by Steven E. Greer, MD
The clinical adoption of Transcatheter Aortic Valve Replacement (TAVR) has been slower than Continue reading
April 12, 2013- Interviewed by Steven E. Greer, MD
William O’Neill, MD, Director of the Structural Heart Disease Center at Henry Ford Hospital, Continue reading
March 26, 2013
Which smartphone apps will the FDA label as a medical device making them taxable tax under Continue reading
March 26, 2013 Interviewed By Steven E. Greer, MD Continue reading
March 10, 2013 By Steven E. Greer, MD The Healthcare Channel
PREVAIL, the much anticipated second major trial of the Boston Scientific device called Watchman was a bust. The trial endpoints were changed in midstream of the trial, but it still did not help. The efficacy endpoint was not met this time, contradicting the first major trial, PROTECT, where a small efficacy was found. (Even if the statistical endpoints were met, the primary endpoint was a clinically meaningless composite of stroke, systemic embolization, and cardiovascular caused death.)
The safety of the device has always been the show stopper. Continue reading
March 10, 2013 By Steven E. Greer, MD The Healthcare Channel
The main reason that Medicare has limited coverage for the Edwards Lifesciences (EW) Sapien percutaneous aortic valve is the high perioperative complication rate of ischemic strokes, in excess of 9%, as well as femoral artery complications. The newer second generation Sapien XT, with a smaller diameter “French” profile, was hoped to reduce the complications and make the TAVR procedure safer. The newest data on the second-gen Sapien do not seem to support the claims from Marty Leon, financial backer of the valve, that the new valve is safer.
The PARTNER II study was presented at the ACC meeting in San Francisco. Continue reading
March 8, 2013 By Steven E. Greer, MD
We interviewed three of the oncologists and industry executives who spoke at the Damon Runyon Continue reading
Prashant Yadav, PhD, Director, Health Care Research Initiative, University of Michigan, discusses Continue reading
Gerald Brandacher, MD, Scientific Director of the Composite Tissue Allotransplantation (Reconstructive Transplant) Program at Johns Hopkins discusses the first double arm transplant.
Greer SE. Inside ObamaCare’s Grant-Making. Op-Ed in The Wall Street Journal. June 4, 2012
Greer SE. Pork is Clogging CMMI’s Arteries. Letter section in The Wall Street Journal. June 20, 2012
Interviewed by Steven E. Greer, MD
Barbara Giesser, MD, neurologist and Medical Director of the Multiple Sclerosis Center at UCLA, discusses the Continue reading
Manal F. Abdelmalek, MD, MPH, of the Duke Medical Center’s Division of Gastroenterology/Hepatology Continue reading
June 30, 2012, by Steven Greer, MD
The Supreme Court ruled that the PPACA “ObamaCare” law was constitutional in most aspects. Continue reading
June 24, 2012
CBS News interviewed the Governor of Massachusetts, Deval Patrick, about the cost increases Continue reading
Center for Medicare and Medicaid Innovation Director Richard Gilfillan’s reply (Letters, June 14) to my op-ed of June 5 says that my accusations “are baseless.” This was backed up with no supporting evidence to refute my claims. He simply states that the contract company which operated the grant review reported no malfunctions. But that was the maddening part of my CMMI experience: CMMI did not seem to want to acknowledge any flaws in its system. Perhaps the reason for this was to allow the CMS officials to claim, “There is no record of any other complaints that the system to review applications wasn’t working.”
I sent an email to Dr. Gilfillan and his boss, Health and Human Services Secretary Kathleen Sebelius, so Dr. Gilfillan’s claim that he received no reports of complaints about the system is false. My peer-review team also sent complaints.
After my op-ed, and despite a new House oversight investigation having been initiated, CMMI is still rushing out more political favors in the form of “grants” to beat the Supreme Court ruling on the ObamaCare law. On June 15 CMMI announced 81 more “Innovation awards,” with each grant in the order of $20 million.
June 4, 2012- In the Wall Street Journal Op-Ed section– by Steven E. Greer
Early this year, I was briefly involved with one of the Affordable Care Act’s bureaucracies called Continue reading
April 5, 2010 Opinion By Steven E. Greer, MD
The New York Times recently ran a front-page story raising concern about expanding the indication for statins to people with normal cholesterol levels, per the Crestor JUPITER trial. The article mentioned the new data in Lancet that suggest a diabetes risk from taking statins and compared that risk to the low absolute benefit from the statins. As has become common practice in the mainstream media, Dr. Steve Nissen was interviewed and quoted in the article. Dr. Nissen has been paid by AstraZeneca, maker of Crestor, and many other drug companies, but states that the funds were donated to charity and that there were no tax deduction benefits to him. Continue reading